Ticagrelor is an orally administered, antiplatelet agent that inhibits ADP's prothrombotic effects on the platelet by antagonizing the P2Y 12 receptor. Ticagrelor is a reversibly binding direct-acting P2Y 12 antagonist and does not require metabolic activation to achieve its antiplatelet effect. CYP3A4 and CYP3A5 appear to be the enzymes predominantly responsible for the formation of the ticagrelor active and inactive metabolites, AR-C124910XX and AR- Studies with recombinant enzymes suggested that cytochrome b5 and CYP3A4 interactions play a significant role in this differential kinetic behavior. Evaluated in fresh human hepatocytes at concentration up to 20 µM, ticagrelor was not an inducer of CYP1A2 or CYP3A4. Though ticagrelor exhibited a tendency for CYP2B6 and CYP2C9 induction, its potential to cause drug interactions via the induction of these enzymes is low when considering its exposure at a therapeutic dose.
INTRODUCTION
Ticagrelor (Fig. 1) is the first of a new class of antiplatelet agents known as cyclo-pentyltriazolo-pyrimidines (CPTPs). Ticagrelor inhibits ADP's prothrombotic effects on the platelet by antagonizing the P2Y 12 receptor. Ticagrelor nearly completely inhibited ADP-induced platelet aggregation ex vivo (Husted et al., 2006) , and ticagrelor demonstrated a dose-dependent inhibition of platelet aggregation in humans, resulting in 79% and 95% inhibition by 90 mg bid and 180 mg bid, respectively (Storey et al., 2007) . Ticagrelor is differentiated from thienopyridine antiplatelet agents such as ticlopidine, clopidogrel and prasugrel, in several important ways. Ticagrelor is an orally active reversibly binding antagonist and does not require metabolic transformation to inhibit P2Y 12 . Conversely, the thienopyridines do require metabolic activation and bind irreversibly to the P2Y 12 receptor. These characteristics may make ticagrelor a drug with faster onset and offset of action, compared to clopidogrel, with less inter-patient variability in plasma concentrations and antiplatelet effects (Gurbel et al., 2009 ).
In addition to the active parent compound, AR-C124910XX (a major metabolite of ticagrelor) has also been found to antagonize the P2Y 12 receptor at approximately equal potency After a 100 mg b.i.d. dose in humans, ticagrelor reaches steady state C max of about 1.5 μ M, while AR-C124910XX circulates in plasma at about one third the concentration of the parent drug (van Giezen and Humphries, 2005; Husted et al., 2006) . Ticagrelor and AR-C124910XX were observed as the predominant components in plasma and feces in six human subjects receiving single oral dose of 14 C-ticagrelor. Recoveries of ticagrelor and AR-C124910XX in urine were both below 1% of the administered dose. The major components in urine were an inactive 5 Ticlopidine, the first thienopyridine antiplatelet agent, is mainly metabolized by CYP3A4
and CYP2C19 (Dalvie and O'Connell, 2004) . Multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, are responsible for the metabolism of clopidogrel (Kazui et al., 2010) while CYP3A4 and CYP2B6 have been identified as major contributors to the metabolism of prasugrel (Rehmel et al., 2006) . Ticlopidine, clopidogrel and prasugrel have been shown to be mechanism-based inhibitors of CYP2B6 (Richter et al., 2004; Nishiya et al., 2009 ) and ticlopidine was also demonstrated as a mechanism-based inhibitor of CYP2C19 (HaDuong et al., 2001) . Unlike reversible inhibitors, mechanism-based inhibition of P450 enzymes can result in time-extended and less predictable changes in exposure to other 'victim' drugs that are subject to metabolism by the inactivated enzyme because the inactivated P450 enzyme can only be replaced by newly synthesized protein.
The current studies were performed to characterize the P450 enzymes that are responsible for the metabolism of ticagrelor to its major active (AR-C124910XX) and inactive (AR-C133913XX) metabolites. In addition, ticagrelor was evaluated in vitro for its potential to inhibit, inactivate or induce major human P450 enzymes. Microsomes expressing individual human cytochrome P450 enzymes, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5 at 150 pmol/mL, were incubated with ticagrelor to evaluate the individual P450 contribution to the metabolism of AR-C124910XX and AR-C133913XX. Incubation conditions and sample preparation were similar as described above. The ticagrelor metabolites formed in the presence of individual P450 were compared to the formation in microsomes from vector control Sf9 membranes.
Material and Methods

Materials
Enzyme kinetics for the formation of AR-C124910XX and AR-C133913XX were evaluated in HLM (0.5 mg/mL), and in recombinant CYP3A4 and CYP3A5 enzymes (150 pmol/mL). Ticagrelor was incubated for 30 min in the concentration range of 1 to 50 µM.
Separation of ticagrelor, AR-C124910XX and AR-C133913XX was performed by reverse phase HPLC utilizing a Phenomenex Synergi Max-RP column (4 µm, 3 × 30 mm) with 5 min gradient at 0.6 mL/min consisting of 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). Compounds were quantified on Finnigan AQA single quadrupole mass spectrometer (ThermoQuest, San Jose, CA) using selected ion monitoring (SIM) mode with ion m/z at 523.0 for ticagrelor, 479.0 for AR-C124910XX and 371.0 for AR-C133913XX. (Burke et al., 1985) , on-line radio detection (Sonderfan et al., 1987) value was estimated where the inhibition exceeded 50% of the control activity. respectively. Metabolite of probe substrate for each enzyme was analyzed using HPLC with UV absorbance (Stresser et al., 2004) . Fold of induction was calculated as the ratio of activity from ticagrelor or positive control to activity from vehicle control. The extent of enzyme activity induction, expressed as a percentage of the positive control effect, was calculated as follows:
Time-dependent
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This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2 . AR-C133913XX was not detected in vector-control, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19 or CYP2D6 incubations. CYP3A5 generated a low amount of AR-C133913XX whereas the profile in the CYP3A4 incubation showed significant AR-C133913XX formation. Small amounts of AR-C124910XX were detected in the incubations with CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19 or CYP2D6;
however, similar amounts were also detected in vector control incubations, indicating these P450
enzymes are unlikely to be responsible for the metabolism of AR-C124910XX. In contrast, significant amounts of AR-C124910XX were detected in both CYP3A4 and CYP3A5
incubations. In addition, metabolites AR-C124910XX and AR-C133913XX were not observed after ticagrelor incubations with human recombinant CYP2E1 and CYP2C8 (data not shown).
The formation of AR-C124910XX and AR-C133913XX from ticagrelor in the presence and absence of selective P450 inhibitors in HLM was also evaluated to confirm the results from recombinant enzymes (Fig. 3) . More than 95% of AR-C124910XX and AR-C133913XX formation was inhibited by 1 μ M of ketoconazole, the selective CYP3A4/5 inhibitor. Other P450 inhibitors, including furafylline for CYP1A2, sulfaphenazole for CYP2C9, and quinidine for CYP2D6, demonstrated little impact on the metabolism of ticagrelor to AR-C124910XX and AR-C133913XX. Omeprazole, a CYP2C19 substrate/inhibitor, exhibited ~40% inhibition for both metabolites at 50 μ M. However, the inhibition may be due to the lack of specificity, as omeprazole has also been shown to inhibit CYP3A4/5 mediated 1'-hydroxymidazolam formation
This article has not been copyedited and formatted. The final version may differ from this version. The maximal activation of 1'-hydroxylation (152%) was observed at 5.6 µM of ticagrelor in vitro, with some decrease effect at higher ticagrelor concentrations.
Ticagrelor did not cause time-dependent inhibition of 1'-hydroxy (Fig. 6A ) or 4-hydroxy (data not shown) midazolam formation in HLM. Verapamil, a known CYP3A inactivator, demonstrated an inactivation rate of 0.04 min -1 at 10 µM (Fig. 5A) . No time-dependent inhibition of CYP2B6 activity by ticagrelor was observed, while 1 μ M ticlopidine inactivated buprobion hydroxylation at a rate of 0.08 min -1 (Fig. 6B) .
In Vitro Interaction between Ticagrelor and Midazolam. The interactions between ticagrelor and midazolam in CYP3A4 and CYP3A5 were studied using the recombinant enzymes
and Cyt b5 addition. In the presence of Cyt b5, the formation of 1'-hydroxymidazolam in CYP3A4 appeared to be activated by ticagrelor. This activation exhibited a maximum increase in metabolism rate at 5.6 µM of ticagrelor, the same concentration as observed in HLM (Fig. 5 and Fig. 7A ). Different ratios of CYP3A4 to Cyt b5 (1:3 vs. 1:10) in the incubation did not change the level of activation of 1'-hydroxylation although this activation was not observed in the absence of Cyt b5 or when denatured Cyt b5 was added to the incubation. The availability of Cyt b5 had little impact on the observed inhibition of midazolam 4-hydroxylation by ticagrelor in recombinant CYP3A4 (Fig. 7B) . No activation of either midazolam hydroxylation catalyzed by CYP3A5 was observed under any tested condition. Ticagrelor weakly inhibited 1'-hydroxylation by CYP3A5 with IC 50 values greater than 50 µM (Fig. 7C) , and moderately inhibited 4-hydroxylation with apparent IC 50 values of 3.1 to 6.3 µM in different ratio of CYP3A5 and Cyt b5 (Fig. 7D) .
CYP Induction by Ticagrelor. The potential of ticagrelor to induce expression of P450 enzymes was evaluated using fresh human hepatocytes. Cytotoxicity assay using tetrazole MTT
DMD # 37143
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 8) . No induction of CYP1A2 activity was observed following 0.2, 2 or 20 µM ticagrelor treatment. CYP1A2 activity data correlated reasonably well with mRNA (Fig. 9) . No induction of CYP1A1 mRNA expression was observed after ticagrelor treatment at any concentration, while BNF increased CYP1A1 mRNA levels by 8.9 fold, when evaluated in one of the three donor cells.
CYP2B6 activity was increased 2.1 to 3.6 fold by 20 µM ticagrelor treatment, or an average of 13.4% of the PB response. Less than 3% of the PB induced CYP2B6 activity was observed following 0.2 and 2 µM ticagrelor treatment (Fig. 8) . Less than 3-fold CYP2B6 mRNA expression increase was observed in hepatocyte donors treated with 0.2, 2, 20 µM ticagrelor, or below 10% of PB response (Fig. 9 ), similar to CYP2B6 activity changes. A small concentration-related increase in CYP2C9 activity was observed with 0.2, 2 and 20 µM ticagrelor treatment in all 3 preparations of human hepatocyte cultures. The responses observed with 20 µM ticagrelor treatment were in the range of 36.5% to 55.9% of the RIF response (Fig.   8 ). However, no induction of CYP2C9 mRNA expression with treatment of ticagrelor was observed at any concentration tested in any donor (Fig. 9) . No induction of CYP3A4 activity was observed in any of the 3 human hepatocytes preparations after ticagrelor treatment at concentrations up to 20 µM (Fig. 8) . CYP3A4 mRNA expression did increase after treatment with ticagrelor, but was below 15% of the RIF response (Fig. 9) .
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Discussion.
Ticagrelor is an orally active antiplatelet agent. AR-C124910XX is the major active metabolite observed in plasma, while AR-C133913XX is an inactive metabolite mainly found in urine. In the current study, the P450 enzymes involved in the conversion of ticagrelor to AR-C124910 and AR-C133913 in vitro were identified. Another purpose of this study was to explore the potential of ticagrelor to cause drug-drug interactions resulting from inhibition, inactivation or induction of the human major P450 enzymes.
CYP3A4 and CYP3A5 appear to be the enzymes mainly responsible for the formation of the active ticagrelor metabolite, AR-C124910XX. CYP3A4 is also likely to be the major enzyme that forms AR-C133913XX, with less contribution from CYP3A5. Other P450 enzymes are likely to be much less important in the metabolism of ticagrelor. CYP3A4 is the predominant human hepatic and intestinal P450 isoform and is responsible for the metabolism of about 50% of clinically used drugs (Guengerich, 1999) . CYP3A5 is polymorphic, where the CYP3A5*3 and CYP3A5*6 alleles are the variants that cause alternative splicing and protein truncation resulting in the absence of CYP3A5 in certain subjects (Kuehl et al., 2001) . CYP3A5
contributes about 17% of total hepatic CYP3A content in about 10% of Caucasians (WestlindJohnsson et al., 2003) . Drugs that modulate CYP3A4 and CYP3A5 activities (such as ketoconazole and diltiazem) and genetic differences in CYP3A5 expression in human volunteers and patients might affect the clearance of ticagrelor in vivo. This article has not been copyedited and formatted. The final version may differ from this version. CYP2C19, CYP2E1 and 0.11 for CYP2D6, suggesting that ticagrelor has low tendency to inhibit these enzymes in vivo.
P450 induction demonstrates significant interspecies differences and primary human hepatocytes are the preferred model for enzyme induction studies as they relate to prediction of drug-drug interactions (LeCluyse, 2001) . The current study demonstrated that ticagrelor is not an inducer of CYP1A2 or CYP3A4. Although ticagrelor caused more than a 2-fold induction in CYP2B6, the relative response did not exceed 15% of positive control response in any of the three donors, indicating ticagrelor is a weak inducer of CYP2B6. Even though a concentrationrelated CYP2C9 activity increase was observed in primary human hepatocyte cultures, only treatment at 20 µM ticagrelor exhibited 35.5% to 55.9% of rifampicin response, while treatment at 0.2 and 2 µM exhibited less than 15% of positive control response. Considering 20 µM is about 13 times the C max concentration in vivo, the potential of ticagrelor at pharmacologically relevant concentrations to cause CYP2C9 or CYP2B6 inductive drug interactions is low.
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This article has not been copyedited and formatted. The final version may differ from this version. (Turpeinen et al., 2005) . A clinical study also showed that a 60-mg prasugrel loading dose, followed by a 10-mg daily maintenance dose for 10 days pretreatment increased AUC of bupropion by 18% and decreased AUC of hydroxybupropion by 23% (Farid et al., 2008) . Our study showed that ticagrelor was not a mechanism-based inhibitor of CYP2B6 and is not likely to cause interactions with drugs primarily metabolized by CYP2B6 in vivo.
Complex interactions were observed between ticagrelor and different CYP3A4/5
substrates. Ticagrelor exhibited partial inhibition towards testosterone 6β-hydroxylation, activation of 1'-hydroxylation and inhibition of 4-hydroxylation midazolam in HLM. A similar differential kinetic pattern was observed in recombinant CYP3A4 in the presence of Cyt b5, but not in recombinant CYP3A5. In vitro activation of P450 enzymes is not uncommon (Zhang et al., 2004; Hummel et al., 2004) , though regioselective heterotropic cooperativity has mainly been observed for CYP3A4. Testosterone has been reported to inhibit 1'-hydroxylation of midazolam and stimulate 4-hydroxylation pathway in HLM and recombinant CYP3A4 (Wang et al., 2000) .
Similar heterotropic activation/inhibition by testosterone towards midazolam and other benzodiazepines has also been demonstrated in intact human hepatocytes (Hallifax et al., 2008) , suggesting the activation effect of testosterone was not an artifact associated only with microsomes. A number of models including multiple binding domains/sites and multiple conformers (Ueng et al., 1997; Korzekwa et al., 1998; Koley et al., 1995) have been proposed to DMD # 37143 This article has not been copyedited and formatted. The final version may differ from this version. describe these experimental observations. However, these hypotheses mainly focus on the heterotropic cooperativity characteristics caused by an effector, rather than by another protein.
Cyt b5 usually acts as the source of the second electron in the P450 catalytic cycle, which enhances the activity of cytochrome P450 enzymes (Schenkman and Jansson, 2003) . Cyt b5 has also been reported to decrease CYP3A4 substrate inhibition by triazolam (Schrag and Wienkers, 2001 ), or induce positive cooperativity of CYP3A4 in the metabolism of pyrene (Jushchyshyn et al., 2005) . In addition, Cyt b5 has also been demonstrated to modulate a CYP3A4 conformational change to stimulate 7-benzyloxyquinoline metabolism (Kumar et al., 2005) . Our study has revealed that the addition of Cyt b5 resulted in CYP3A4 activation in the metabolism of 1'-hydroxymmidazolam. However, the full appreciation of the complex interaction between ticagrelor and midazolam in CYP3A4 was beyond the scope of the current work.
In summary, the results of the current in vitro studies suggest ticagrelor is mainly metabolized by CYP3A4 and CYP3A5 and has the possibility to be inhibited when co- This article has not been copyedited and formatted. The final version may differ from this version. 
